Pharmaceuticals
Sequoia leads $50m round for China's Adagene
Sequoia Capital China has led an oversubscribed $50 million Series C funding round for Chinese biotechnology company Adagene.
China’s Hua Medicine gets $117m
Hua Medicine, a Chinese clinical-stage biotechnology company, has closed a combined Series D and Series E funding round at $117.4 million with support from a group of VCs.
IMM secures 2x return on Korea pharma investments
IMM Private Equity has fully exited its investments in Korean pharmaceutical developers Handok and Genexine.
Chinese GPs back AstraZeneca spin-out
A consortium led by Boyu Capital, 6 Dimensions Capital and Hillhouse Capital will invest up to $250 million in Viela Bio, a pharmaceutical research and development company being spun out from AstraZeneca.
Allergan to acquire Australia's VC-backed Elastagen
Allergan, a US-listed pharmaceutical company and the owner of Botox cosmetic injectable products, has agreed to acquire Elastagen, an Australian skin treatment developer backed by a number of VCs, in a deal worth up to $260 million.
Sailing invests $30.6m in China-US biopharma player
Sailing Capital has invested $30.6 million in Cellular Biomedicine Group (CBMG), a China and US-based biopharmaceutical company focused on immunotherapy cancer treatments.
Asia VCs invest $10m in US-Singapore biotech player
A group of VCs led by China’s 6 Dimensions Capital and Sino-US investor Danhua Capital (DHVC) has committed $10 million to US and Singapore-based Engine Biosciences.
Advantech, SDIC lead $76m round for China biotech player
Advantech Capital and SDIC Fund Management have led a $76 million Series A round for Chinese biotechnology company KBP Biosciences.
Temasek leads $80m round for Singapore biopharma player
Singapore’s Temasek Holdings has led an $80 million funding round for domestic biopharmaceutical company Tessa Therapeutics with support from a number of venture and growth capital investors.
Mekong exits Vietnam's Traphaco for $64.5m
Vietnam’s Mekong Capital has exited its 25% stake in domestic pharmaceuticals company Traphaco for about $64.5 million. It represents a gross return multiple of 6.3x for the investment.
Healthcare funds: Repeat prescription
An assortment of healthcare-focused GPs – most of them in China – have emerged to leverage rising domestic consumption and nascent medical innovation. Does domain expertise mean better deal access?
China's EOC Pharma closes $32m Series B
EOC Pharma, a China-based cancer treatment specialist, has closed a $32 million Series B funding round led by Taikang Industry Development Fund.
India’s Samara acquires drug portfolio from Novartis
Samara Capital Partners has acquired the Indian rights to a portfolio of drug brands from Swiss pharmaceutical company Novartis.
OrbiMed invests $42.5m in India's Vivimed Labs
Healthcare specialist investor OrbiMed has committed $42.5 million in Uquifa, the active pharmaceutical ingredient (API) unit of India-listed pharmaceuticals business Vivimed Labs.
China's XW Laboratories raises $17.5m Series B
Chinese biopharmaceuticals developer XW Laboratories has raised a $17.5 million Series B funding round led by WI Harper and Elements Capital.
TPG acquires Taiwan healthcare player
TPG Capital has acquired a controlling stake in Taiwan’s OPC Holding, a contract research organization that offers clinical trial services across a number of medical fields.
Sequoia, Sofina lead $30m round for India’s MedGenome
Sequoia Capital India and Belgian investor Sofina have led a $30 million Series C round for MedGenome, an India and US-based company focused on molecular biology research and diagnostics.
Deal focus: Just delivers on cross-border promise
Lilly Asia Ventures, Arch Ventures and Temasek have backed the expansion of Just Biotherapeutics' China-based manufacturing and research operation
Deal focus: VCs to rebalance Indian shortcoming
Lifestyle changes due to economic development in India are impacting the country's disease patterns. Fidelity International is bringing much needed venture capital to a medical research space addressing the issue
Temasek leads $57m round for China biotech firm
Singapore’s Temasek Holdings has led a $57 million Series B round for Chinese drug developer Hangzhou Just Biotherapeutics (Just China).
Eight Roads, F-Prime invest $25m in India's PlasmaGen
Indian biopharmaceuticals company PlasmaGen BioSciences has raised a $25 million funding round led by Eight Roads Ventures.
French VC joins $13m round for Japanese biopharma player
France-based venture capital firm Seventure Partners has joined a $13.1 million funding round for Japanese biopharmaceuticals development company Anaeropharma Science.
Carlyle, PEP to pay $930m for Australian pharma player
The Carlyle Group and Pacific Equity Partners (PEP) have finalized an agreement to jointly acquire Australia-based iNova Pharmaceuticals for $930 million in cash.
Australian VCs invest $16m in domestic drug developer
Australian VC investors Brandon Capital and Uniseed have committed $16 million to Que Oncology, a clinical-stage drug development company established by the University of Queensland (UQ) and US-based Emory University.